IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd. (NASDAQ:ICCM) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 111,279 shares, a decrease of 65.8% from the June 30th total of 325,222 shares. Based on an average trading volume of 298,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 3.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ICCM. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Maxim Group lowered their target price on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Alliance Global Partners assumed coverage on shares of IceCure Medical in a report on Monday, May 4th. They set a “buy” rating on the stock. Finally, Wall Street Zen raised shares of IceCure Medical to a “sell” rating in a research note on Sunday, July 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, IceCure Medical presently has a consensus rating of “Hold” and a consensus target price of $62.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ICCM. Virtu Financial LLC acquired a new position in shares of IceCure Medical during the 4th quarter worth approximately $39,000. Concurrent Investment Advisors LLC bought a new stake in IceCure Medical in the 4th quarter valued at $48,000. Finally, Jane Street Group LLC acquired a new stake in IceCure Medical during the 4th quarter valued at $67,000. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Stock Down 3.1%

NASDAQ:ICCM opened at $2.79 on Wednesday. The firm has a market capitalization of $9.57 million, a price-to-earnings ratio of -0.39 and a beta of 0.43. IceCure Medical has a twelve month low of $2.12 and a twelve month high of $42.00. The stock’s 50 day moving average price is $4.72 and its two-hundred day moving average price is $11.27.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The firm had revenue of $0.91 million for the quarter, compared to the consensus estimate of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. As a group, analysts anticipate that IceCure Medical will post -3.51 earnings per share for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.